Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Terminated

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Outcome
Stopped early. Results posted; no analysis attachedStudy terminated due to safety issues. (Toxicity)
Phase
Phase 1 / Phase 2
Status
Terminated
Study type
Interventional
Start
18 May 2016
Ended
13 February 2019
Enrollment
137 participants
Sites
18
Primary outcomes
Number of Participants With Treatment Emergent Adverse Events (TEAE's).
Sponsor type
Industry
Results posted
28 April 2022
Last update
21 October 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 21 October 2025
Primary outcome
Number of Participants With Treatment Emergent Adverse Events (TEAE's).Part1/Treatment Group A : 8mg QD INCB057643: 4, n = 4Part1/Treatment Group A : 12mg QD INCB057643: 5, n = 5Part1/Treatment Group A : 16mg QD INCB057643: 8, n = 8Part1/Treatment Group B : 8mg QD INCB057643: 7, n = 7Part1/Treatment Group B : 12mg QD INCB057643: 5, n = 5Part1/Treatment Group C : 8mg QD INCB057643: 1, n = 1Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort: 86, n = 86Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort: 5, n = 5Values: ParticipantsTime frame: From screening through at least 30 days after end of treatment, up to approximately 24 monthsNo analysis posted for this outcome (outcome 1)
Participants
Part1/Treatment Group A : 8mg QD INCB057643: 4 started, 0 completedPart1/Treatment Group A : 12mg QD INCB057643: 5 started, 0 completedPart1/Treatment Group A : 16mg QD INCB057643: 8 started, 0 completedPart1/Treatment Group B : 8mg QD INCB057643: 7 started, 0 completedPart1/Treatment Group B : 12mg QD INCB057643: 5 started, 0 completedPart1/Treatment Group C : 8mg QD INCB057643: 1 started, 0 completedPart2/Treatment Group A : 12 mg INCB057643 Expansion Cohort: 86 started, 0 completedPart2/Treatment Group B : 12 mg INCB057643 Expansion Cohort: 5 started, 0 completedPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg: 1 started, 0 completedPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg: 2 started, 0 completedPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg: 4 started, 0 completedPart3/Treatment Group D : 8 mg INCB057643 + Abir +Predni: 3 started, 0 completedPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg: 1 started, 0 completedPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg: 2 started, 0 completedEnrolled But Not Dosed: 3 started, 0 completed
Serious adverse events
Part1/Treatment Group A : 8mg QD INCB057643: 2 of 4Part1/Treatment Group A : 12mg QD INCB057643: 1 of 5Part1/Treatment Group A : 16mg QD INCB057643: 4 of 8Part1/Treatment Group B : 8mg QD INCB057643: 5 of 7Part1/Treatment Group B : 12mg QD INCB057643: 4 of 5Part1/Treatment Group C : 8mg QD INCB057643: 1 of 1Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort: 32 of 86Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort: 4 of 5Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg: 0 of 1Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg: 0 of 2Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg: 0 of 4Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni: 1 of 3Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg: 1 of 1Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg: 0 of 2Participants with at least one serious adverse event, of those at risk, as posted
9 secondary outcomes, the first 8 shown
Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administ…
C1D1: 8mg QD INCB057643 24 (199.5), n=11; 12mg QD INCB057643 28 (200.1), n=51; 16mg QD INCB057643 54 (236.3), n=7 [mean %Inhibition of Total c-Myc, Standard Error] (first of 2 rows)
ORR · Objective Response Rate (ORR) With INCB057643 in Solid Tumors
Solid Tumors: Part1/Treatment Group A : 8mg QD INCB05… 0, n=3; Part1/Treatment Group A : 12mg QD INCB0… 0, n=4; Part1/Treatment Group A : 16mg QD INCB0… 0, n=6; Part2/Treatment Group A : 12 mg INCB057… 0, n=63; Part3/Treatment Group A : 8 mg INCB0576… 0, n=1; Part3/Treatment Group B : 8 mg INCB0576… 1, n=2; Part3/Treatment Group C : 8 mg INCB0576… 0, n=4; Part3/Treatment Group D : 8 mg INCB0576… 0, n=3 [Participants] (first of 7 rows)
Cmax: Maximum Observed Plasma Concentration of INCB057643.
C1D1: 8mg QD INCB057643 201 (83.6), n=12; 12mg QD INCB057643 266 (94.7), n=99; 16mg QD INCB057643 343 (93.2), n=7 [mean nM, Standard Deviation] (first of 2 rows)
Tmax: Time to Maximum Plasma Concentration of INCB057643
C1D1: 8mg QD INCB057643 2.00 (1.00 to 24.00), n=12; 12mg QD INCB057643 2 (0.50 to 8.00), n=99; 16mg QD INCB057643 2.00 (2.00 to 4.00), n=7 [median hours, Full Range] (first of 2 rows)
AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643
8mg QD INCB057643 2090 (50.1), n=12; 12mg QD INCB057643 2550 (39.5), n=99; 16mg QD INCB057643 3210 (34.3), n=7 [mean h*nM, Standard Deviation]
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Admini…
8mg QD INCB057643 1940 (45.1), n=10; 12mg QD INCB057643 2740 (43.2), n=89; 16mg QD INCB057643 3610 (71.9), n=7 [mean h*nM, Standard Deviation]
Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.
12mg QD INCB057643 220 (32.0), n=11 [mean nM, Standard Deviation]
Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643
12mg QD INCB057643 6.00 (4.00 to 8.00), n=11 [median hours, Full Range]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 in select tumor types including solid tumors, lymphomas and other hematologic malignancies. Part 3 will determine the tolerated dose of INCB057643 in combination with select SOC agents; and assess the safety and tolerability of the combination therapy in select advanced solid tumors and hematologic malignancies. Part 4 will further evaluate the safety, preliminary efficacy, PK, and PD of the selected dose combination from Part 3 in 4 specific advanced solid tumor and hematologic malignancies.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Number of Participants With Treatment Emergent Adverse Events (TEAE's). [From screening through at least 30 days after end of treatment, up to approximately 24 months]. Number, Participants. Part1/Treatment Group A : 8mg QD INCB057643 (n=4): 4; Part1/Treatment Group A : 12mg QD INCB057643 (n=5): 5; Part1/Treatment Group A : 16mg QD INCB057643 (n=8): 8; Part1/Treatment Group B : 8mg QD INCB057643 (n=7): 7; Part1/Treatment Group B : 12mg QD INCB057643 (n=5): 5; Part1/Treatment Group C : 8mg QD INCB057643 (n=1): 1; Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort (n=86): 86; Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort (n=5): 5; Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg (n=1): 1; Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg (n=2): 2; Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg (n=4): 4; Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni (n=3): 3; Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg (n=1): 1; Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg (n=2): 2.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay [PD in plasma at pre-dose and 0.5, 1, 2, 4, 6 and 8 hours postdose, for C1D1 and C1D8, and 24hrs post dose for C1D1]. Mean, %Inhibition of Total c-Myc (Standard Error). C1D1: 8mg QD INCB057643 (n=11): 24 (199.5); 12mg QD INCB057643 (n=51): 28 (200.1); 16mg QD INCB057643 (n=7): 54 (236.3). C1D8: 8mg QD INCB057643 (n=11): 30 (42.59); 12mg QD INCB057643 (n=51): 43.4 (52.7); 16mg QD INCB057643 (n=7): 65 (55.21).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Objective Response Rate (ORR) With INCB057643 in Solid Tumors [Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months]. Number, Participants. Solid Tumors: Part1/Treatment Group A : 8mg QD INCB057643 (n=4): 0; Part1/Treatment Group A : 12mg QD INCB057643 (n=5): 0; Part1/Treatment Group A : 16mg QD INCB057643 (n=8): 0; Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort (n=86): 0; Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg (n=1): 0; Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg (n=2): 1; Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg (n=4): 0; Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni (n=3): 0. Lymphoma: Part1/Treatment Group A : 8mg QD INCB057643 (n=4): 1; Part1/Treatment Group A : 12mg QD INCB057643 (n=5): 0; Part1/Treatment Group A : 16mg QD INCB057643 (n=8): 1; Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort (n=86): 2. AML: Part1/Treatment Group B : 8mg QD INCB057643 (n=7): 0; Part1/Treatment Group B : 12mg QD INCB057643 (n=5): 0; Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort (n=5): 1; Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg (n=2): 0. Glioblastoma: Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort (n=86): 0. Myelodysplastic Syndrome: Part1/Treatment Group B : 8mg QD INCB057643 (n=7): 0; Part1/Treatment Group B : 12mg QD INCB057643 (n=5): 0; Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort (n=5): 0. Myelofibrosis: Part1/Treatment Group B : 8mg QD INCB057643 (n=7): 0; Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort (n=5): 0; Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg (n=1): 0. Multiple Myeloma: Part1/Treatment Group C : 8mg QD INCB057643 (n=1): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Cmax: Maximum Observed Plasma Concentration of INCB057643. [Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8]. Mean, nM (Standard Deviation). C1D1: 8mg QD INCB057643 (n=12): 201 (83.6); 12mg QD INCB057643 (n=99): 266 (94.7); 16mg QD INCB057643 (n=7): 343 (93.2). C1D8: 8mg QD INCB057643 (n=12): 210 (93.2); 12mg QD INCB057643 (n=99): 293 (113); 16mg QD INCB057643 (n=7): 340 (165).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Tmax: Time to Maximum Plasma Concentration of INCB057643 [Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8]. Median, hours (Full Range). C1D1: 8mg QD INCB057643 (n=12): 2.00 (1.00 to 24.00); 12mg QD INCB057643 (n=99): 2 (0.50 to 8.00); 16mg QD INCB057643 (n=7): 2.00 (2.00 to 4.00). C1D8: 8mg QD INCB057643 (n=12): 1.00 (1.00 to 4.00); 12mg QD INCB057643 (n=99): 2 (0.50 to 8.00); 16mg QD INCB057643 (n=7): 2.00 (2.00 to 4.00).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643 [Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1]. Mean, h*nM (Standard Deviation). 8mg QD INCB057643 (n=12): 2090 (50.1); 12mg QD INCB057643 (n=99): 2550 (39.5); 16mg QD INCB057643 (n=7): 3210 (34.3).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy [Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D8]. Mean, h*nM (Standard Deviation). 8mg QD INCB057643 (n=10): 1940 (45.1); 12mg QD INCB057643 (n=89): 2740 (43.2); 16mg QD INCB057643 (n=7): 3610 (71.9).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643. [C2D1]. Mean, nM (Standard Deviation). 12mg QD INCB057643 (n=11): 220 (32.0).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643 [C2D1]. Median, hours (Full Range). 12mg QD INCB057643 (n=11): 6.00 (4.00 to 8.00).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy [C2D1]. Mean, h*nM (Standard Deviation). 12mg QD INCB057643 (n=11): 2980 (31.5).